iCAD Expands Executive Leadership with Appointment of Mark Koeniguer as Chief Commercial Officer

Core Viewpoint - iCAD, Inc. has appointed Mark Koeniguer as Chief Commercial Officer to drive global growth and enhance its AI-powered breast health solutions [1][2]. Company Overview - iCAD, Inc. is a leader in providing AI-powered solutions for early cancer detection, particularly in breast health, with its ProFound Breast Health Suite used in over 50 countries [5]. - The company has estimated that it has read more than 40 million mammograms in the last five years, with nearly 30% being tomosynthesis [5]. Leadership Appointment - Mark Koeniguer brings over 30 years of experience in MedTech, AI, and digital health, previously serving as CEO of ScreenPoint Medical, where he increased annual recurring revenue by 400% [3]. - In his role as CCO, Koeniguer will oversee commercial sales teams, partnerships, operations, and customer success, focusing on revenue growth in North America and globally [2][4]. Strategic Goals - The appointment of Koeniguer is aimed at better engaging with global health providers and enhancing clinical workflows and patient experiences [4]. - The leadership believes Koeniguer's expertise in radiological health and AI solutions will be instrumental in advancing iCAD's mission to transform breast cancer detection [4].